Rate My Professor Pratima Chowdary

Professor Pratima Chowdary is Professor of Haemophilia and Haemostasis in the Research Department of Haematology at University College London and Haemophilia Centre Director at the Katharine Dormandy Haemophilia and Thrombosis Centre, Royal Free London NHS Foundation Trust. Qualified with MBBS, MRCP, and FRCPath, she has been a consultant haematologist for more than 15 years, specializing in the management of patients with inherited and acquired bleeding and thrombotic disorders. She serves as Clinical Service Lead for haemophilia, rheumatology, and haematology at the Trust. As Chair of the UK Haemophilia Centre Doctors' Organisation and co-director of the UK National Haemophilia Database, she plays a pivotal leadership role in national haemophilia care. Professor Chowdary is a member of the International Society on Thrombosis and Haemostasis, British Society for Haemostasis and Thrombosis, European Association for Haemophilia and Allied Disorders, and World Federation of Haemophilia.

Her research specializations encompass strategies for personalised haemophilia management, clinical outcomes improvement, biomarkers for joint disease, and novel assays for bleeding diathesis and thrombotic tendency. She has acted as chief investigator for numerous academic and commercial clinical trials, including gene therapy and novel treatments for severe haemophilia, and oversaw the development of a biobank at the Royal Free Hospital. Professor Chowdary has authored over 100 peer-reviewed publications and three textbook chapters. Notable works include 'Phase 1–2 Trial of AAVS3 Gene Therapy in Patients with Hemophilia B' in the New England Journal of Medicine (2022), 'Haemophilia' in The Lancet (2025), and 'Bioengineered Factor VIII — More Innovation for Hemophilia A' editorial in the New England Journal of Medicine (2024). She has chaired working parties, data safety monitoring boards, and trial steering committees, and served as a panel member for the National Institute for Health Research Health Technology Assessment Programme in the UK and Norway, contributing significantly to advancements in haemostasis and haemophilia treatment.